Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Hepatogastroenterology ; 61(135): 2068-76, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25713912

RESUMEN

BACKGROUND/AIMS: High operative mortality has been reported after liver resection for hepatocellular carcinoma (HCC) in cirrhotic patients with high preoperative serum alanine aminotransferase (sALT) level. Their long-term prognosis has never been investigated. The aim of this study is to evaluate the benefit of liver resection for HCC in this subgroup of patients. METHODOLOGY: A retrospective review of the medical records of 978 cirrhotic patients who underwent curative liver resection for HCC between 2000 and 2012 was conducted. The preoperative sALT level of 218 patients was > 100 U/l (normal 5 -50) (group 1). The clinicopathological characteristics as well as early and long-term results after hepatectomy of group 1 were compared with those of the other 760 cirrhotic patients whose sALT was < 100 U/l (group 2). Liver resection extent was decided by tumor extent and a modified version of Makuuchi's criteria. RESULTS: Group 1 patients had a significantly higher indocyanine 15-minute retention rate, higher hepatitis infection rates and a higher rate of macronodular cirrhosis. Although group 1 patients had a higher postoperative complication rate, the complication severity and 90-day mortality did not significantly differ. In 81.2 % of group 1 patients, sALT level returned to the normal range within 12 weeks after operation. The 5-year disease-free and overall survival rates in group 1 and 2 were 55.1% and 57.5% (P = 0.540) and 51.5% and 60.9%, (P=0.485), respectively. CONCLUSIONS: Liver resection for HCC remains advisable in selected cirrhotic patients with preoperatively high sALT level when liver resection extent fulfills Makuuchi's criteria for cirrhotic liver resection.


Asunto(s)
Alanina Transaminasa/sangre , Biomarcadores de Tumor/sangre , Carcinoma Hepatocelular/cirugía , Hepatectomía , Cirrosis Hepática/cirugía , Neoplasias Hepáticas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Hepatocelular/sangre , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/mortalidad , Supervivencia sin Enfermedad , Femenino , Hepatectomía/efectos adversos , Hepatectomía/mortalidad , Humanos , Estimación de Kaplan-Meier , Cirrosis Hepática/sangre , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/mortalidad , Neoplasias Hepáticas/sangre , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/mortalidad , Masculino , Persona de Mediana Edad , Selección de Paciente , Complicaciones Posoperatorias/mortalidad , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento , Regulación hacia Arriba , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...